Lawrence County deputies issue 54 tickets during Click It or Ticket campaign
The Lawrence County Sheriff's Office took part in Missouri's 2025 Click It or Ticket campaign from May 10 to June 1. Deputies issued 54 citations and warnings, including three seat belt violations, 26 for speeding, two DWIs, and 23 other traffic offenses. One felony arrest was also made.
Lawrence County deputies issue 54 tickets during Click It or Ticket campaign
Hearing on wastewater permits for animal feeding operations
Governor Kehoe requests federal disaster aid for six Missouri counties
Woman killed in SW Missouri crash was pregnant with twins, police say
Head-on collision in Marionville claims life, injures two
Sheriff Brad DeLay reminded drivers that seat belts are the best defense in a crash and urged everyone to 'Buckle Up and Arrive Alive.'
Missouri's current seat belt use rate is 88.3 percent, below the national average of 91.2 percent. Teens and pickup truck drivers remain the least likely to buckle up at 74.0 percent and 75.3 percent, respectively.
More info is available at saveMOlives.com.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Heavy police presence in Gibson City Monday afternoon
GIBSON CITY, Ill. (WCIA) — There is a heavy police presence in Gibson City Monday afternoon. The officers are in the area of IL-54 and N 300 E Road. Two officers shot in Gibson City, Suspect sought A WCIA reporter on the scene said the officers appear to be searching a field. This is a developing story. We will share updates as we learn more. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Business Upturn
13 hours ago
- Business Upturn
Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company's innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth. Regen sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market projected to be valued at well in excess of $1 billion annually. HemaXellerate is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation. Advertisement HemaXellerate is comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells. 'Aplastic anemia patients without access to bone marrow transplantation face limited options,' said Dr. David Koos, Chairman and CEO of Regen BioPharma. 'With FDA clearance to begin clinical trials, HemaXellerate has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders. This is a pivotal moment for our company as we work to deliver life-changing therapies to patients worldwide.' To ensure the trial's success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months. Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity. Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market. Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence. About Regen BioPharma, Inc. Regen BioPharma, Inc. is a publicly traded biotechnology company (OTC ID: RGBP) and (OTC ID: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effect of government regulation, competition and other material risks. CONTACT INFORMATION: Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-722-5505 Phone Email: [email protected] or [email protected] X (formerly twitter): Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Wire
16 hours ago
- Business Wire
Together Women's Health Named to Inc. 5000 List for Third Consecutive Year
DETROIT--(BUSINESS WIRE)--Together Women's Health (TWH) proudly announces its inclusion on the 2025 Inc. 5000 list for the third year in a row. This honor places Together Women's Health among the most dynamic businesses in America across all industries. Together Women's Health is a women's health-focused management service organization, committed to partnering with leading physicians to build a premier network of women's health services in the U.S. TWH's affiliate network consists of 20 practices with nearly 200 providers delivering women's health services at 57 locations throughout Michigan, Illinois, Alabama, Colorado, Mississippi, Missouri, Georgia, Tennessee and Kentucky. Being named to the Inc. 5000 list for the third year in a row is a tremendous honor and a testament to the extraordinary network of women's healthcare providers who serve patients with excellence every day across the country Share The Inc. 5000 ranking celebrates companies that have achieved rapid revenue growth while demonstrating resilience, innovation, and leadership in their fields. Together Women's Health's recognition highlights the organization's commitment to advancing women's healthcare through strategic partnerships with top physicians, investment in clinical and operational excellence, and a patient-first approach to care. 'Being named to the Inc. 5000 list for the third year in a row is a tremendous honor and a testament to the extraordinary network of women's healthcare providers who serve patients with excellence every day across the country,' said Anthony Ahee, Founder and CEO of Together Women's Health. 'This recognition also reflects the dedication of our incredible team, whose passion for elevating and innovating women's health is making a real difference in the lives of the patients and communities we serve.' Together Women's Health is a growing network of leading women's healthcare practices committed to delivering exceptional, individualized care for women at every stage of life. The organization partners with leading physicians to build a premier network of women's health services in the U.S.—from routine gynecologic and obstetric care, breast health, advanced gynecologic procedures, menopause management, urogynecology, maternal fetal medicine, and more. With a focus on clinical and operational excellence, innovation, and compassionate care, Together Women's Health empowers providers to thrive while elevating the patient experience. The recognition on the 2025 Inc. 5000 list follows a year of significant milestones, including expanding into new states, adding maternal-fetal medicine expertise, and opening an Imaging Center dedicated to breast health. To learn more about a partnership with Together Women's Health, visit or contact us at partner@ About Together Women's Health Headquartered in Detroit, MI, Together Women's Health ('TWH') is a women's health management services organization committed to partnering with leading physicians to build a premier network of obstetricians and gynecologists. TWH, recently named on the Inc. 5000 list of fastest growing companies in America, supports its affiliated practices and physician partners throughout multiple states with strategic guidance, administrative resources (including revenue cycle management, marketing, human resources, finance, accounting, and IT), operational expertise and capital, thereby allowing physicians to focus on clinical excellence and serving their communities. TWH is building a network of top clinicians in a physician-led culture. For more information about Together Women's Health, please visit About Shore Capital Partners Shore Capital, a Chicago-based private equity firm with offices in Nashville, is an investor in lower middle market companies in the Healthcare, Food and Beverage, Business Services, Industrial, and Real Estate industries. Shore's strategy is to support management partners to grow faster with less risk through access to capital, world-class board and operational resources, and unmatched networking, development, and shared learnings across the portfolio. From 2020-2024, Shore received recognition from Inc Magazine as a 5x Top Founder Friendly Investor and by Pitchbook Research for leading U.S. Private Equity deal volume for the past 10 years, from 2015-2024. Shore targets investments in proven, successful private companies with superior management teams, stable cash flow, and significant potential to grow through industry consolidation and organic growth to generate value for shareholders. Shore has approximately $13 billion of assets under management and in additional investment platforms to which it provides business and operational consulting services. To learn more about Shore Capital Partners, please visit
